Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
Drakaki A, Kirby C, van der Heijden M, Petrylak D, Powles T, N. K, Fléchon A, Necchi A, Géczi L, Lee J, Gakis G, Bracarda S, Chowdhury S, Lin C, Keizman D, Vaishampayan U, Zimmermann A, Bell-McGuinn K, Castellano D. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer 2020, 6: 43-52. DOI: 10.3233/blc-190252.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalOverall response ratePrior immune checkpoint inhibitorsUrothelial carcinomaCheckpoint inhibitorsPlatinum-refractory metastatic urothelial carcinomaUnstratified Cox proportional hazards modelMedian progression-free survivalPlatinum-refractory urothelial carcinomaImproved progression-free survivalPre-specified subgroup analysisCox proportional hazards modelMetastatic UC patientsMetastatic urothelial carcinomaAdvanced urothelial carcinomaKaplan-Meier methodSubgroup of patientsProportional hazards modelICI therapyUC patientsDocetaxel armMost patientsAdverse eventsARM patients